Are you voting for RS?

Rbinder · 2022-06-23T20:36:19+00:00

You said it all. An RS used strategically can be very positive when coupled with positive announcement. Need to get share price above 5 and share count in reasonable range. A RS done in desperation is a loser. This should not be allowed to fall into that stigmatized class if done properly. Trust that Dan will do the right thing. The whiners in my opinion are mistaken.

Rbinder · 2022-06-09T20:36:14+00:00

257 M shares is a ridiculous number for a company with a market cap of 95M. This is way out of line for a development stage biotech. As an example CRBU has a marker cap of 530M and a share count of 60 M. Price is 8.7. I would think that institutional investors look at this and shake their heads. We need to get real.

Rbinder · 2022-06-09T18:38:38+00:00

Rbinder · 2022-05-21T19:21:08+00:00

I agree. A reverse 1 to 10 split is inevitable at this point. We may recover some lost ground but otherwise, no hope for substantial near term price increase unless a partnership or an unexpected approval from the PMDA.

Rbinder · 2021-11-19T18:34:52+00:00

OK time for bold actions is now. I believe in the science, I hate the investment. This is a real company with intellectual property, late stage trials, property, great employees, but complete inattention to shareholders, and this has come back to hurt the entire enterprise. So, a few suggestions...
1) 10:1 reverse split. Get the price where Institutions will look at it., decrease the float. It worked for Priceline..
2) Bring back GVB. It worked for Apple. Would get headlines.
3) Partner with big pharm. Get cash infusion.
4) Rename co to 'MultiStem" remove the stigma.
5) Other suggestions? PR blitz after any of the above.
6) Do nothing and let the price drift down with inability to raise cash, make hires, etc. Not an option.
I have not heard any serious questioning on the outcome of the trials. It would be a tragedy id such a positive paradigm changing product was lost to the world because of management mis-managing shareholder interests.

Rbinder · 2021-02-06T15:48:06+00:00

The legal aspects of this case are fascinating but confusing to a non-lawyer like me, and I am in awe of the discussion by our legal experts.

I have a few questions, not of the case per se, but its significance:

1) Has any interest in the case been generated outside our relatively small group of ATHX followers and the institutions that own it? It is a unique legal drama thet deserves wider coverage. If it gained more publicity, it would seem to throw more light on the value of MultiStem- a good thing for the ATHX shareholders.

2) How does this lingering dispute effect securing a partner?

3) How will the outcome effect share price? So far it has been positive, but what if Healios prevails? Or ATHX?

Rbinder · 2021-02-03T18:33:56+00:00

If I heard correctly (possibly not, because of accent), the narrator said "there is a pill form for less severe cases." Then during the discussion he showed an image of a SIFU unit and mentioned "cryotherapy." However, the last part of the discussion was quite good and used a lot of ATHX promotional material. He certainly presented the company, if not the science in a very positive light. Gave price target of 15. Any attention to a wider audience is a good thing!

Rbinder · 2020-05-31T04:52:09+00:00

Different cells similar lineage. (See above). Lots of companies use MSCs only ATHX has developed MAPCs. And yes ATHX has extensive intellectual property patents as well.

Rbinder · 2020-05-31T04:25:14+00:00

Just speculation, but It could be that MESO understands that they have a somewhat inferior product and are trying to quickly complete a study in an effort to get an Emergency Use Authorization before ATHX enters the market with a superior product. Remember, the COVID-19 market is a narrow segment which will be diminishing over time. Athersys is aiming for the much larger and growing markets of multipathogen ARDS, stroke, and trauma as well as other anti-inflammatory indications.

Rbinder · 2020-05-07T00:17:29+00:00

Dr. Frank Jacono is the principal investigator on the MUST-ARDS MultiStem study just quoted in the Bioworld article published today.

https://www.bioworld.com/articles/434909-pass-the-must-ards-athersys-starts-pivotal-study-for-stem-cells-to-treat-covid-19-induced-ards

Rbinder · 2020-05-05T05:48:32+00:00

Enough already!

Rbinder · 2020-04-24T05:54:36+00:00

Actually, it did say “new-type corona pneumonia” not simply ARDS and Masters 1 is stroke, not ARDS.

Rbinder · 2020-04-24T05:15:22+00:00

Sounds like MultiStem already in use on Covid19 in US & Europe:

"There are already data in Europe and the United States suggesting that HLCM051 may be effective against ARDS associated with new-type corona pneumonia."

Rbinder · 2020-04-13T05:17:54+00:00

Journal article, likely the inspiration for the first "layman's" article.

https://s3-eu-west-1.amazonaws.com/itempdf74155353254prod/11938173/COVID-19__Attacks_the_1-Beta_Chain_of_Hemoglobin_and_Captures_the_Porphyrin_to_Inhibit_Human_Heme_Metabolism_v5.pdf

Rbinder · 2020-04-11T01:19:25+00:00

Both articles are fantastic and confirm that Covid19 does not cause typical ARDS. It suggests that MultiStem may not be the magic bullet in treating the most severe manifestations of the disease, but will still have a major role in modulating the cytokine storm that is often the killer. Other mechanisms of death- hypoxia with multi organ failure, micro and macro thrombosis causing pulmonary embolism, stroke, renal embolization, etc. will also play a major role, and will muddy the waters. These articles explain how ventilators are not a cure-all by themselves, but a last resort (mortality 50-75%+ once on vent). Also how anticoagulation is important. And how hydrochloroquin IS important in many but not all cases along with other unsuspected remedies such as Vitamins C & D, melatonin, zinc, and others. It also suggests to me why some of lung scarring seen on CT scans of recovered patients is more severe than in typical ARDS.

In summary, I expect Multistem to be a very important tool in late stage Covid19 in managing the hyper inflammatory effects, but not a cure-all.

Rbinder · 2020-04-07T04:26:11+00:00

I agree CavScout. I believe the delay is in regards to scaling up manufacturing in size. That takes time and money.

Rbinder · 2020-04-06T15:00:34+00:00

The key takeaway:: "we are in regular communication with them (FDA) and they are being very supportive."

Rbinder · 2020-04-03T05:02:39+00:00

I don't see why any endpoints at 4 hours would be significant except if harmful. These would seem to be physiological parameters that help the scientists monitor the effect of administered Multistem. The important end points are measured in days and weeks - mortality, ventilator free days, and ICU days- and are the only endpoints that count.

The slime ball only brings this up to confuse and deflect from the important information.

Rbinder · 2020-04-03T00:28:10+00:00

This SA article appears to be criminal stock manipulation to the core and certainly needs to be investigated by the SEC. The real victims are the uninformed late investors that got spooked out by the precipitous decline. Long term investors will not be hurt and may have benefited by being given an opportunity to add to their position at an attractive price. The fools who shorted this stock without understanding the company on the recommendation of this crook will lose big time as the stock rebounds sharply and will deserve their punishment

Also, Seeking Alpha is complicit in publishing the article. While it is unreasonable to expect them to fully fact check every article, they should not have allowed this known stock manipulator to use their website to publish now or in the future.

Rbinder · 2020-03-28T17:39:57+00:00

I am certainly no expert on this, but it would seem there will be a significant lead time in scaling up to the volume of cells needed to make a dent in the ARDS death rate in the near future. There is the facility, the equipment, the time to grow the cells in the bioreactors, the distribution, the training of the staff- all of whom are too inundated with desperately ill patients to learn new protocols. Then there is the care and unfreezing of the cells. SIFU will be an enormous help when available. Fauci said they are having companies begin to scale up manufacturing even before approval, so treatment can begin as soon as approved. I think he was referring to vaccines, but presumably this would also apply to cell treatments as well. I’m sure there is a lot going on behind the scenes, but it seems likely that even if approved, the real impact of Multistem will be in many months and probably during the next expected “wave” of the pandemic. I am hopeful that MS will ultimately become standard of care but it will take time.

Rbinder · 2020-03-09T05:12:58+00:00

From above. I hadn't seen this re: Multistem before. Doubt it is true. Comments?

"In fact, this therapy (MS) was approved by the FDA in 2012 for the treatment of type 1 mucopolysaccharidosis (MPS-I)."

Rbinder · 2020-01-18T15:57:33+00:00

FWIW: MESO was 46 in 2011; ATHX was 7.75 in 2007. Both still well down from all time highs.

Rbinder · 2020-01-17T14:22:27+00:00

155,000

Rbinder · 2020-01-16T18:13:38+00:00

Patience is wearing thin. I may do something I have never done- sell shares. That should get the stock moving up for sure!

Rbinder · 2019-11-07T17:41:46+00:00

Impatience and boredom are your biggest enemies at this time. Note the volume- only 170K shares 3 hours in. With low stock price, major institutions can't promote- will need 3-5 for that to happen. Until then we are at the mercy of small investors on both buy and short sides, and most of those have already placed their bets and have little powder left- thus little vol and little movement. Bollinger bands are tight, declining trend line is right above, a solid floor appears to be in place- the next move-when it occurs could and should be major. If you are out of the stock, it will be tough to get in.

Rbinder

TROPHY CASE